Company profile: Upstream Bio
1.1 - Company Overview
Company description
- Provider of antibody therapies targeting the TSLP receptor, developing verekitug (UPB-101), a monoclonal antibody in Phase 2 trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), and conducting research on Thymic Stromal Lymphopoietin (TSLP) as a driver of inflammatory responses in allergic and inflammatory diseases.
Products and services
- Clinical Trials: Ongoing Phase 2 clinical-stage trials evaluating verekitug for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps across two indications
- TSLP Research: Mechanistic research studying Thymic Stromal Lymphopoietin as a key driver of inflammatory responses in allergic and inflammatory diseases
- Verekitug (UPB-101): Phase 2 clinical-stage monoclonal antibody that inhibits the TSLP receptor, targeting TSLP-mediated inflammatory responses in severe asthma and chronic rhinosinusitis with nasal polyps
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Upstream Bio
Genespire
HQ: Italy
Website
- Description: Provider of transformative gene therapies for genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Offers Immune Shielded Lentiviral Vectors for direct liver use enabling long-term hepatocyte-specific expression for one-time treatments, and an Advanced Gene Editing Platform enabling high-efficacy, permanent targeted gene integration in T-cells and HSPCs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genespire company profile →
Aditxt
HQ: United States
Website
- Description: Provider of biotechnology solutions using novel nucleic acid-based technologies, including AditxtScore for personalized immune profiling; Apoptotic DNA Immunotherapy (ADI) to induce immune tolerance for transplants, autoimmune diseases, and allergies; Adimune for restoring immune tolerance; Pearsanta for personalized diagnostic and monitoring services; and Adivir developing medicines, diagnostics, and vaccines for public health threats.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aditxt company profile →
Grifols
HQ: Spain
Website
- Description: Provider of healthcare solutions operating in Bioscience, Hospital, and Diagnostic segments. The Bioscience segment engages in the research, development, production, and commercialization of plasma derivates. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing diagnostics products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Grifols company profile →
Phenex Pharmaceuticals
HQ: Germany
Website
- Description: Provider of drug discovery and development focused on novel pharmaceuticals, leveraging small-molecule expertise. Privately held, founded in 2002, with Biology and Chemistry laboratories and offices in the Biotech Cluster Rhine-Neckar, primarily in Heidelberg and partly in Ludwigshafen.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phenex Pharmaceuticals company profile →
Q32 Bio
HQ: United States
Website
- Description: Provider of therapies for severe autoimmune and inflammatory diseases, including bempikibart (ADX-914), a fully human anti–IL-7 receptor alpha antagonist monoclonal antibody that blocks IL-7 and TSLP signaling to re-regulate adaptive immune function, and ADX-097, a humanized anti-C3d monoclonal antibody fusion protein aimed at restoring complement regulation via a tissue-targeted mechanism.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Q32 Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Upstream Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Upstream Bio
2.2 - Growth funds investing in similar companies to Upstream Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Upstream Bio
4.2 - Public trading comparable groups for Upstream Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →